DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» G1 Therapeutics
G1 Therapeutics
Positive Effects of Trilaciclib on Patient
Investor Day March 6, 2019
G1 Therapeutics Presents Two Posters at ISPOR Describing The
In Bladder Cancer
METASTATIC TRIPLE NEGATIVE BREAST CANCER (Mtnbc) PATIENTS: PRELIMINARY PHASE 2 RESULTS JOYCE OʼSHAUGHNESSY1, GAIL S
G1 Therapeutics Provides First Quarter 2020 Corporate and Financial Update
G1 Corporate Presentation
G1 Therapeutics Announces Initiation of Phase 1B/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer
Effect of Trilaciclib, a CDK 4/6 Inhibitor, on Myelosuppression in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer
Breast Cancer
Trilaciclib (G1t28): a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Etoposide and Carboplatin
Myeloprotection
Daniel Et Al., Abstract #1742PD
G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA™ (Trilaciclib) in Non-Small Cell Lung Cancer (PRESERVE 4)
G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights
G1 Therapeutics Receives Fast Track Designation from U.S
American Society of Clinical Oncology (ASCO)
COSELA Safely and Effectively
Top View
COSELA Kickoff Analyst & Investor Summit Presentation
Phase II Two-Arm Study of Tepotinib + Osimertinib in Patients with EGFR-Mutant NSCLC and Acquired
Study Protocol G1T28-02 Eudract # 2016-001583-11
G1 Therapeutics Provides Second Quarter 2020 Corporate and Financial Update
G1 Therapeutics Presents Updated Data at ESMO 2019 From
G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto Rico
Preclinical Characterization of G1T28: a Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression John E
G1 Therapeutics and Astrazeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung Cancer
G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual Meeting
Breast Cancer
G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer
(G1t48), an Oral Selective Estrogen Receptor Degrader, in Combination with Palbociclib for Er+/Her2– Advanced Breast Cancer: Phase 1 Results
Trilaciclib Improves Overall Survival When Given with Gemcitabine
G1 Corporate Presentation
In Triple-Negative Breast Cancer (TNBC)
G1 Therapeutics Presents Final Phase 2 Clinical Data on Trilaciclib In
FDA Approves Therapy to Protect Bone Marrow Cells from Effects of Chemotherapy 19 February 2021
Sorrentino Et Al., Abstract #377
COSELA (Trilaciclib)
TRILACICLIB IMPROVES OVERALL SURVIVAL WHEN GIVEN with GEMCITABINE/CARBOPLATIN (Gcb) in PATIENTS with METASTATIC TRIPLE NEGATIVE
FDA Approves G1 Therapeutics' COSELA™ (Trilaciclib)